Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024 (Businesswire) - Nov 15, 2024 - "Aurinia Pharmaceuticals...announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN)...and reinforce the clinical importance of LUPKYNIS (voclosporin)...for the treatment of adults with active LN....An analysis from the Phase 3 AURORA 1 and 2 studies highlighted the long-term efficacy of LUPKYNIS in people with LN. This study focused on a new efficacy endpoint, sustained complete renal response (SCRR), defined by the United States Food and Drug Administration (FDA) as achieving a complete renal response (CRR) at 12 months in AURORA 1 and at all study visits in the 2-year AURORA 2 continuation study....The SCRR endpoint was included in an FDA-approved label update for LUPKYNIS earlier this year."
P3 data • Patient reported outcomes • Lupus Nephritis • Systemic Lupus Erythematosus
|